NICE Rejects Vemurafenib for Melanoma Citing Costs

The National Institute of Clinical Excellence's (Nice) decision not to recommend Vemurafenib as a treatment option for melanoma patients since it is too expensive has attracted criticism from a skin cancer patient support group.

NICE Rejects Vemurafenib for Melanoma Citing Costs

Factor 50 has urged Nice to reconsider its decision to not recommend the drug as it could prove to be a "potentially lifesaving" drug and added that the decision was same as passing a death sentence.

Vemurafenib, manufactured by Roche, costs around Ģ1,750 per patient per week and though Roche was willing to offer an undisclosed discount for the NHS, Nice decided that it was not cost effective.

"Standard treatments that have been available since the 1970s are ineffective and to deny this drug to patients, is tantamount to passing them a death sentence. I am astonished and deeply worried that Nice has not given approval to yet another drug which will significantly alter the lives of melanoma patients", Factor 50's chief executive officer Gill Nuttall said.

Your comments are automatically posted once they are submitted. All comments are however constantly reviewed for spam and irrelevant material (such as product or personal advertisements, email addresses, telephone numbers and website address). Such insertions do not conform to our policy and 'Terms of Use' and are either deleted or edited and republished.Please keep your comments brief and relevant.This section may also have questions seeking help. If you have the information you are welcome to respond, but please ensure that the information so provided is genuine and not misleading.

Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.Full Disclaimer